Factor de Crecimiento de Fibroblastos 21 Sérico (FGF21s) como biomarcador diagnóstico y pronóstico en pacientes con carcinoma celular renal de células claras (CCRCC).

KNOTT ME; ROULET L; MINATTA N; BRZEZINSLI M; MALAGRINO H; NUÑEZ M; RANUNCOLO SM; PURICELLI LI; DE LORENZO MS

CABA

Congreso; Reunión de Trabajo y Actualizaciones Post-ASCO 2015. Asociación Argentina de Oncología Cínica (AAOC).; 2015

Asociación Argentina de Oncología Clínica (ASCO)

PURPOSE. The finding of new biomarkers is needed to have a better sub-classification of primary renal tumors (RCC) as well as more reliable predictors of outcome and therapy response. In this study, we evaluated the role of circulating FGF21, an endocrine factor, as a diagnostic and prognostic biomarker for ccRCC. INTRODUCTION. Primary renal tumors (RCC) comprise a heterogeneous group of entities with diverse morphological and molecular characteristics, with variable and unpredictable clinical outcomes. Clinicians face important pitfalls in the treatment of RCC, such as absence of symptoms in early stages of the disease, its high metastatic potential and its resistance to conventional therapy. Clear-cell renal cell carcinoma (ccRCC) is the most frequent malignant neoplasm of the renal parenchyma. It is considered as a cell metabolism disease. Fibroblast Growth Factor 21 (FGF21) has emerged as a potentially key molecule able to regulate local and systemic metabolic homeostasis.MATERIALS AND METHODS. Serum samples from 50 healthy controls (HC) and 98 clear cell and chromophobe RCC cancer patients were obtained from the serum biobank "Biobanco Público de Muestras Séricas Oncológicas" (BPMSO) of the ?Instituto de Oncología ?Ángel H. Roffo?. Levels of FGF21 and leptin were measured by ELISA while other metabolic markers were measured following routinary clinical procedures. RESULTS. One of our major findings was that FGF21 levels were significantly increased in ccRCC patients compared with HC. Moreover, we showed an association between the increased levels of serum FGF21 and the shorter disease free survival in a cohort of 98 ccRCC patients, after adjustment for other predictors of outcome. CONCLUSION. Our results suggest that high levels of FGF21 showed to be an independent prognostic biomarker, associated with worse free-disease survival.